# Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)

> **NCT04787354** · PHASE3 · RECRUITING · sponsor: **Hallym University Medical Center** · enrollment: 976 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT04787354
- **Lead sponsor:** Hallym University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 976 (ESTIMATED)
- **Last updated:** 2022-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04787354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04787354, "Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04787354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*